{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:57:26Z","timestamp":1782917846709,"version":"3.54.5"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Mesothelin is an attractive target for CAR T therapy on a number of cancer types; however, the efficacy of this therapy is diminished because the bulk of the cell surface-expressed mesothelin is shed through naturally occurring proteolysis leaving behind a short juxtamembrane peptide \u201cstump\u201d. The two problems this creates are one, the bulk of the target protein is no longer on the tumor cell and two, soluble, shed mesothelin persists in the tumor microenvironment and circulates in blood and other body fluids, where it can bind mesothelin-targeted CAR T cells and act as a decoy that reduces engagement with tumor cell\u2013surface mesothelin. These issues have contributed at least in part to the lack of desired efficacy in human clinical trials utilizing CAR T cells that target membrane distal regions of mesothelin (i.e., the shed domain) such as those utilizing the variable domains of anti-mesothelin monoclonal antibodies SS1 and M5. In addition, there have been safety concerns regarding the targeting of mesothelin on normal tissues. Here we describe CAR T cells that utilize novel phage display-derived antibodies specific for the mesothelin stump domain, thus being unaffected by the natural process of mesothelin shedding. Mesothelin \u201cstump-specific\u201d CAR T cells (CAR 422) had cytotoxicity and\n                    <jats:italic>in vivo<\/jats:italic>\n                    activity that were comparable to previously studied anti-mesothelin CAR T cells. Importantly, CAR 422 T cells were effective against tumor cells that were resistant to conventional anti-mesothelin CAR T cells and showed reduced on-target\/off tumor toxicity in a human mesothelin knock-in mouse model. Thus, CAR 422 holds potential as a next-generation therapy for challenging solid tumors.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1805950","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:37:52Z","timestamp":1782916672000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"John","family":"Scholler","sequence":"first","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Song","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Deshmukh","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Decheng","family":"Song","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatuna","family":"Gabunia","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ji","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimin","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Jia","family":"Fan","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Gulendran","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don L.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"B2","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (Sage)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing Cd28 and Cd137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor Mrna-engineered T cells induce anti-tumor activity in solid Malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted Car-T cell therapy for solid tumors","volume":"21","author":"Klampatsa","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33145","article-title":"Phase 1 study of the immunotoxin Lmb-100 in patients with mesothelioma and other solid tumors expressing mesothelin","volume":"126","author":"Hassan","year":"2020","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-21-0407","article-title":"A phase I trial of regional mesothelin-targeted Car T-cell therapy in patients with Malignant pleural disease, in combination with the anti-Pd-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-0351","article-title":"Expression of a functional Ccr2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted Car T cell therapy generates potent and long-lasting Cd4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03556-7","article-title":"Functional enhancement of mesothelin-targeted Truc-T cells by a Pd1-Cd28 chimeric switch receptor","volume":"72","author":"McCarthy","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2023.2182058","article-title":"Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (Truc) exhibit potent antitumor efficacy against solid tumors","volume":"12","author":"Ding","year":"2023","journal-title":"Oncoimmunology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01093-7","article-title":"From Tcr fundamental research to innovative chimeric antigen receptor design","volume":"25","author":"Minguet","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012822","article-title":"Tandem Car-T cells targeting mesothelin and Muc16 overcome tumor heterogeneity by targeting one antigen at a time","volume":"13","author":"Salas-Benito","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-3841","article-title":"Mesothelin Car T cells secreting anti-Fap\/anti-Cd3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01572-0","article-title":"Generating potent and persistent antitumor immunity via affinity-tuned Car-T cells targeting mesothelin","volume":"46","author":"Yue","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for Ca125\/Muc16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101440","article-title":"Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment","volume":"21","author":"Zhang","year":"2022","journal-title":"Transl Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.01.011","article-title":"Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity","volume":"26","author":"Chu","year":"2024","journal-title":"Cytotherapy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202439119","article-title":"Highly active Car T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin","volume":"119","author":"Liu","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317283121","article-title":"Tumor resistance to anti-mesothelin Car-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope","volume":"121","author":"Liu","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/abt\/tbaf022","article-title":"Ro4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy","volume":"9","author":"Onda","year":"2026","journal-title":"Antib Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.381756","article-title":"Recognition of mesothelin by the therapeutic antibody Morab-009: Structural and mechanistic insights","volume":"287","author":"Ma","year":"2012","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.06.006","article-title":"Two cases of severe pulmonary toxicity from highly active mesothelin-directed Car T cells","volume":"31","author":"Haas","year":"2023","journal-title":"Mol Therapy: J Am Soc Gene Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: Ready for prime time","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-19-0688","article-title":"Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases","volume":"18","author":"Avula","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s42003-020-01464-5","article-title":"Multiple proteases are involved in mesothelin shedding by cancer cells","volume":"3","author":"Liu","year":"2020","journal-title":"Commun Biol"},{"key":"B30","first-page":"9.1","article-title":"Generation of antibody libraries: Pcr amplification and assembly of light- and heavy-chain coding sequences","volume-title":"Phage Display: A Laboratory Manual","author":"Andris-Widhopf","year":"2001"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.2004638","article-title":"Development of a fully canine anti-canine Ctla4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors","volume":"13","author":"Mason","year":"2021","journal-title":"MAbs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2287250","article-title":"Development and pharmacokinetic assessment of a fully canine anti-Pd-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors","volume":"15","author":"Yoshimoto","year":"2023","journal-title":"MAbs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1056","article-title":"Imgt(R), the International Immunogenetics Information System(R) 25 years on","volume":"43","author":"Lefranc","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"Psma-targeting Tgf\u03b2-insensitive armored Car T\u2009cells in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012885","article-title":"Reinfusion of Cd19 Car T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia","volume":"8","author":"Myers","year":"2024","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade2526","article-title":"Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma","volume":"9","author":"Uslu","year":"2023","journal-title":"Sci Adv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310382559","article-title":"Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: History, experience, methodology, and future directions","volume":"38","author":"Leach","year":"2010","journal-title":"Toxicol Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104872","article-title":"Classic and evolving approaches to evaluating cross reactivity of Mab and Mab-like molecules - a survey of industry 2008-2019","volume":"121","author":"MacLachlan","year":"2021","journal-title":"Regul Toxicol Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2393785","article-title":"The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics","volume":"16","author":"Norden","year":"2024","journal-title":"MAbs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/biom10070973","article-title":"Mesothelin-targeted recombinant immunotoxins for solid tumors","volume":"10","author":"Hagerty","year":"2020","journal-title":"Biomolecules"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: Phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/cancers15051357","article-title":"Challenges of anti-mesothelin Car-T-cell therapy","volume":"15","author":"Zhai","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/01926233241311259","article-title":"Applications of cell-based protein array technology to preclinical safety assessment of biological products","volume":"53","author":"Vicart","year":"2025","journal-title":"Toxicol Pathol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.str.2026.02.012","article-title":"Off-target reactivity in clinical monoclonal antibodies","volume":"34","author":"Dai","year":"2026","journal-title":"Structure"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2026-431","article-title":"A new approach methodology (Nam) for specificity testing: Istand qualification of the membrane proteome array to evaluate off-target binding of Mab-based therapies","volume-title":"Proceedings of the American Association for Cancer Research Annual Meeting","author":"Norden","year":"2026"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen Ca125\/Muc16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.186268","article-title":"Affinity-tuned mesothelin Car T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: Expanding Car T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0054","article-title":"Generation of potent T-cell immunotherapy for cancer using Dap12-based, multichain, chimeric immunoreceptors","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"Car T cell therapy for patients with solid tumours: Key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/jci169655","article-title":"Antitumor activity of azd0754, a dntgf\u03b2rii-armored, steap2-targeted car-t cell therapy, in prostate cancer","volume":"133","author":"Zanvit","year":"2023","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.01.012","article-title":"Adoptive t cell immunotherapy for medullary thyroid carcinoma targeting gdnf family receptor alpha 4","volume":"20","author":"Bhoj","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot108602","article-title":"Phage display selection of antibody libraries: panning procedures","volume":"2026","author":"Peng","year":"2026","journal-title":"Cold Spring Harb Protoc"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot108603","article-title":"Phage display selection of antibody libraries: screening of selected binders","volume":"2026","author":"Peng","year":"2026","journal-title":"Cold Spring Harb Protoc"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn316","article-title":"Imgt\/v-quest: the highly customized and integrated system for ig and tr standardized v-j and v-d-j sequence analysis","volume":"36","author":"Brochet","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp946","article-title":"Imgt\/3dstructure-db and imgt\/domaingapalign: a database and a tool for immunoglobulins or antibodies, t cell receptors, mhc, igsf and mhcsf","volume":"38","author":"Ehrenmann","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136012","article-title":"A rational mouse model to detect on-target, off-tumor car t cell toxicity","volume":"5","author":"Castellarin","year":"2020","journal-title":"JCI Insight"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1805950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:37:54Z","timestamp":1782916674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1805950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1805950"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1805950","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1805950"}}